MedTrace Logo

Vessel Density in nAMD After Longterm Anti-VEGF Treatment Compared to Recently Started Anti-VEGF Treatment

NCT03833830 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-10-01

No results posted yet for this study

Summary

Neovascular age-related macular degeneration (nAMD) is characterized by the abnormal growth of blood vessels from the choroid into the subretinal space which leads to sub- and intraretinal fluid accumulation, hemorrhages and subretinal fibrosis with progressive loss of central vision. Intravitreal anti-VEGF treatment is the standard of care. Intravitreal anti-VEGF application might temporarily increase intraocular pressure due to a volume effect. It remains unclear if repeated injections might have an impact on retinal capillary perfusion. Therefore this study aims to investigate the vascular microcirculation differences between patients who received longterm intravitreal Anti-VEGF treatment and patients who recently started Anti-VEGF treatment using Optical Coherence tomography Angiography (OCTA).

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DIAGNOSTIC_TEST

Optical Coherence Tomography angiography (OCTA)

There will be an OCTA measurement (observational study) for both groups. Group allocation will be made due to previous anti-VEGF treatments (longterm treatment group \>20 injections and shortterm treatment group \< 5 injections).

Sponsors & Collaborators

  • Cenaug Foundation

    collaborator UNKNOWN

  • Dr. med. Katja Hatz

    lead OTHER

Principal Investigators

  • Katja Hatz, MD · Vista Klinik Binningen

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-07
Primary Completion
2019-04-02
Completion
2019-05-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03833830 on ClinicalTrials.gov